ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
36 announcements with these filters
Metropolis Healthcare Ltd reported revenue from operations of ₹424.7 Cr (+23.0% YoY) and net profit of ₹51 Cr (+74.7% YoY) for Q4 FY26.
Metropolis Healthcare reported its financial results and declared an interim dividend totaling ₹20.73 Crore. The board also recommended Deloitte Haskins & Sells as new statutory auditors.
Metropolis Healthcare allotted 4,200 equity shares and granted 2,26,581 new stock benefits. The ₹0.00084 Crore allotment follows employee stock option exercises and RSU plan vesting.
Metropolis Healthcare Ltd has scheduled a Board Meeting for May 13, 2026. The board will consider audited FY26 financial results and the declaration of a second interim dividend for FY26. Consequently, the company's trading window remains closed until May 15, 2026.
Metropolis Healthcare Limited submitted its quarterly compliance certificate for the period ended March 31, 2026, as per SEBI (Depositories and Participants) Regulations. The certificate, issued by its registrar MUFG Intime India, confirms that security certificates received for dematerialisation were processed and listed on the stock exchanges within prescribed timelines.
Metropolis Healthcare reported ~23% Y-o-Y consolidated revenue growth for Q4FY26, driven by the TruHealth wellness and specialized testing segments. B2B and B2C channels grew 30% and 19% respectively. Organic revenue increased ~14.5%, supported by improved EBITDA margins and volume growth across diagnostic segments.